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Adult Leukemia Survival Trends in the United States by  
Subtype: A Population-Based Registry Study of 370,994  
Patients Diagnosed During 1995-2009
Chris Bailey, MB ChB, MSc, MRCP1; Lisa C. Richardson, MD, MPH2; Claudia Allemani, MSc, PhD, FHEA, HonMFPH1; 
Audrey Bonaventure, MD, PhD1; Rhea Harewood, MSc1; Angela R. Moore, MPH2; Sherri L. Stewart, PhD2;  
Hannah K. Weir, PhD2; Michel P. Coleman, MD1; and CONCORD Working Group (US members)* 
BACKGROUND: The lifetime risk of developing leukemia in the United States is 1.5%. There are challenges in the estimation of popula-
tion-based survival using registry data because treatments and prognosis vary greatly by subtype. The objective of the current study 
was to determine leukemia survival estimates in the United States from 1995 to 2009 according to subtype, sex, geographical area, 
and race. METHODS: Five-year net survival was estimated using data for 370,994 patients from 43 registries in 37 states and in 6 
metropolitan areas, covering approximately 81% of the adult (15-99 years) US population. Leukemia was categorized according to 
principal subtype (chronic lymphocytic leukemia, acute myeloid leukemia, and acute lymphocytic leukemia), and subcategorized in 
accordance with the HAEMACARE protocol. We analyzed age-standardized 5-year net survival by calendar period (1995-1999, 2000-
2004, and 2005-2009), leukemia subtype, sex, race, and US state. RESULTS: The age-standardized 5-year net survival estimates in-
creased from 45.0% for patients diagnosed during 1995-1999 to 49.0% for those diagnosed during 2000-2004 and 52.0% for those 
diagnosed during 2005-2009. For patients diagnosed during 2005-2009, 5-year survival was 18.2% (95% confidence interval [95% 
CI], 17.8%-18.6%) for acute myeloid leukemia, 44.0% (95% CI, 43.2%-44.8%) for acute lymphocytic leukemia, and 77.3% (95% CI, 
76.9%-77.7%) for chronic lymphocytic leukemia. For nearly all leukemia subtypes, survival declined in successive age groups above 45 
to 54 years. Men were found to have slightly lower survival than women; however, this discrepancy was noted to have fallen in succes-
sive calendar periods. Net survival was substantially higher in white than black patients in all calendar periods. There were large dif-
ferences in survival noted between states and metropolitan areas. CONCLUSIONS: Survival from leukemia in US adults improved 
during 1995-2009. Some geographical differences in survival may be related to access to care. We found disparities in survival by sex 
and between black and white patients. Cancer 2018;124:3856-3867. © 2018 American Cancer Society. 
KEYWORDS: cancer, cancer registries, leukemia, National Program of Cancer Registries, population-based survival, Surveillance, 
Epidemiology, and End Results (SEER), United States.
INTRODUCTION
The age-standardized incidence rate of all leukemias combined in adults in the United States is 6.9 per 100,000 popu-
lation per year, with a lifetime risk of developing leukemia of 1.5%.1 Survival among adults with leukemia has been 
improving over the last 30 years, with 5-year survival rising from 33% in 1975 to 59% in 2005.1 As with many cancers, 
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the absolute number of leukemia cases is expected to in-
crease over the coming years, primarily due to the ageing 
population.2
Survival estimates from population-based can-
cer registries typically are lower than those of clinical 
trials because eligibility criteria for trial participants 
often include restrictions based on age or comorbidi-
ties.3 Population-based cancer registries in the United 
States receive federal support from the National 
Cancer Institute’s Surveillance, Epidemiology, and End 
Results program1; the Centers for Disease Control and 
Prevention’s National Program of Cancer Registries4; or 
both. These programs collect data including sex, race, 
tumor behavior, basis of diagnosis, age at diagnosis, and 
date of death or last known follow-up on all new cancer 
cases. These data are used to provide information regard-
ing incidence, survival, prevalence, and mortality. This 
information is crucial to inform policymakers imple-
menting cancer prevention and control strategies.5
Leukemias are categorized by the lineage of the cell 
affected (myeloid vs. lymphoid) and the rapidity of disease 
progression (acute vs. chronic). Within each category, the 
malignant cell may originate from different stages of mat-
uration, taking on unique morphological, cytogenetic, 
and clinical characteristics. As many leukemias are too 
rare to power robust survival estimates, a consensus group-
ing of hematological malignancies was formed as part of 
the European Cancer Registry–based HAEMACARE 
project on hematologic malignancies.6 This grouping is 
based on the World Health Organization classification of 
Tumours of the Haematopoietic and Lymphoid Tissues.7
The CONCORD-2 study established global sur-
veillance of cancer survival in 2015, including data from 
279 registries in 67 countries for 25.7 million patients 
diagnosed during 1995-2009. This included survival 
estimates for all adult patients with leukemia combined 
(873,588 patients worldwide), along with 9 other ma-
lignancies.2 As part of a systematic analysis, this project 
focuses on US adults diagnosed with acute myeloid leu-
kemia (AML), acute lymphocytic leukemia (ALL), and 
chronic lymphocytic leukemia (CLL) during the periods 
1995-1999, 2000-2004, and 2005-2009 and presents 
survival by leukemia subtype, sex, race, and US state or 
metropolitan area.
MATERIALS AND METHODS
Data for 393,805 adult patients (those aged 15-99 years) 
diagnosed with leukemia between January 1995 and 
Figure 1. Participating registries in the analysis of leukemia survival trends in the United States, 1995-2009. †Surveillance, 
Epidemiology, and End Results registries; *National Program of Cancer Registries (bold); Metropolitan registries (italics). [Colour 
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December 2009 were provided by 43 registries in 37 
states and in 6 metropolitan areas that collectively cover 
approximately 81.0% of the US national population 
(Fig. 1). The variables in the data set included a unique 
identifier; sex; age at diagnosis; last known vital status; 
International Classification of Diseases for Oncology, 
3rd edition (ICD-O-3) morphology code; date of diag-
nosis; race (as self-defined by patients); and basis of di-
agnosis (morphological/cytological verification, clinical 
verification, and death certificate only). A total of 10,071 
(2.6%) patient records did not meet the eligibility criteria 
and these patients were excluded. Reasons for exclusion 
comprised data that were incomplete, patients aged out-
side the age range of 15 to 99 years, and diagnoses of 
uncertain or benign behavior. Of records eligible for sur-
vival analysis, those with coding and classification errors, 
invalid dates or date sequences, or incongruence between 
age and morphology were also excluded. Each registry 
was issued 3 data quality reports (protocol adherence, ex-
clusions, and editorial) and were invited to correct any 
inconsistencies identified. In all, 3.3% of patients diag-
nosed based on death certificate only or whose disease 
was detected at autopsy were excluded. 
We categorized leukemias into 3 principal groups: 
acute myeloid leukemia (AML; 34.7%), acute lympho-
cytic leukemia (ALL; 14.0%), and chronic lymphocytic 
leukemia (CLL; 51.3%). Subtypes of leukemia then were 
subdivided further into HAEMACARE groups, which 
were defined by ICD-O-3 morphology codes 9670-9981 
(Table 1).
We examined the distribution of age at diagnosis, 
sex, race, and data quality indicators such as the percentage 
of diagnoses with microscopic verification and patients 
lost to follow-up. Patients were grouped into 3 calendar 
periods of diagnosis: 1995-1999, 2000-2004, and 2005-
2009. We used the 5 age groups set out in the International 
Cancer Survival Standard for age standardization: 15 to 
44, 45 to 54, 55 to 64, 65 to 74, and 75 to 99 years.8 Race 
was coded as “black,” “white,” and “other.” The basis of 
diagnosis was coded as “morphologically verified” if there 
was cytological, histological, or microscopic evidence of 
verification.
Statistical Analysis
We estimated 5-year net survival with the estimator of 
Pohar-Perme et al,9 implemented with the program stns10 
in Stata statistical software (version 14; StataCorp, College 
Station, Texas).11 Net survival is the probability of surviv-
ing up to a given time since diagnosis after controlling for 
competing causes of death (background mortality). The 
cohort approach was used for the calendar periods 1995-
1999 and 2000-2004 because at least 5 years of poten-
tial follow-up were available for all patients. The period 
approach was used for patients diagnosed between 2005 
and 2009 in which 5 years of follow-up were not available 
for all patients. This approach provides a robust short-
term prediction of the eventual cohort-based survival.12
To control for wide differences in background 
mortality, we used the life tables prepared for the 
CONCORD-2 study.13 These contain all-cause mortal-
ity rates in the general population of each state or metro-
politan area by single year of age, sex, and race, for each 
calendar year from 1995 to 2009. For patients with cancer 
whose race was coded as “other,” we used the life tables for 
all races combined. Robust life tables for black patients 
were not available in 6 states in which the black popu-
lation is small (Alaska, Hawaii, Idaho, Montana, New 
Hampshire, and Wyoming). In those 6 states, survival 
estimates for black patients are not presented separately.
Age-standardized net survival was estimated for 
each HAEMACARE group of malignancies, stratified 
by sex, race, and calendar period. When there were fewer 
than 10 patients in a given age group, the data were 
merged with the adjacent age group to create 2 age-spe-
cific estimates. When there were two or more age-specific 
estimates based on fewer than 10 patients, only unstan-
dardized estimates are presented.
Approval for the CONCORD-2 data was obtained 
from the Ethics and Confidentiality Committee of the 
UK Health Research Authority (ECC 3-04(i)/2011) and 
the National Health Service Research Ethics Committee 
(11/LO/0331). Separate statutory and/or human sub-
jects research approvals were obtained from each cancer 
registry.
RESULTS
A total of 370,994 patients were included in the analysis: 
89.1% were white, 7.3% were black, and 3.6% were of 
other race. Men comprised 57.5% of the patients. The 
median age at the time of diagnosis was 69.3 years.
CLL was the most common leukemia for all age 
groups with the exception of those aged 15 to 44 years, 
for whom AML was more frequent (see Supporting 
Table 1). All leukemias were more common in males. For 
HAEMACARE groups, the sex disparity was smallest for 
acute myeloid leukemia (group 22), in which 54.0% of 
those diagnosed were men (Table 2). Burkitt lymphoma 
(10.8%) was most common among black patients, and 
acute (precursor cell) lymphoblastic leukemia was most 
common among other races (5.4%). The number of cases 
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per state ranged from 649 cases (Alaska) to 47,886 cases 
(California). The majority of cases (90.9%) were mor-
phologically verified, ranging from 83.4% (Maryland) to 
99.3% (Florida) (see Supporting Table 2).
For the US overall, age-standardized 5-year net sur-
vival for all sexes, races, and subtypes combined increased 
from 45.0% (95% confidence interval [95% CI], 44.6%-
45.4%) in 1995-1999 to 49.0% (95% CI, 48.7%-49.4%) 
in 2000-2004, to 52.0% (95% CI, 51.6%-52.3%) in 
2005-2009. This represents an absolute increase in 5-year 
net survival of 4.0% between 1995-1999 and 2000-2004, 
and 3.0% between 2000-2004 and 2005-2009.
Survival declined in successive age groups from 45 
to 54 years for nearly all leukemia subtypes (Table 3). 
Gains in survival were highest in the younger age groups. 
For patients with AML between 1995-1999 and 2005-
2009, survival increased by 12.1% in those aged 45 to 
54 years compared with 1.4% in the those aged 75 to 99 
years.
Age-standardized 5-year net survival increased 
for all 3 principal leukemias (Table 4). The greatest 
gains were noted among patients with ALL (5.3% be-
tween 1995-1999 and 2000-2004 and 3.9% between 
2000-2004 and 2005-2009). Among HAEMACARE 
groups, there were large gains for patients with Burkitt 
lymphoma (9.5% [95% CI, 5.3%-13.5%] between 1995-
1999 and 2000-2004 and 4.9% [95% CI, 1.4%-8.4%] 
between 2000-2004 and 2005-2009).
For patients diagnosed during 2005-2009, 5-year 
survival was 18.2% (95% CI, 17.8%-18.6%) for AML, 
44.0% (95% CI, 43.2%-44.8%) for ALL, and 77.3% 
(95% CI, 76.9%-77.7%) for CLL (Table 5). Males 
were found to have slightly lower survival than females 
throughout the 15 years between 1995 and 2009. This 
disparity fell in successive time periods (1.5% in 1995-
1999, 1.1% in 2000-2004, and 0.7% in 2005-2009).
Net survival for white patients was substantially 
higher than that for black patients throughout the 15-
year period, with the absolute difference noted to increase 
(8.3% in 1995-1999, 9.5% in 2000-2004, and 10.9% in 
2005-2009) (Fig. 2). Survival was higher for white than 
for black patients for each of the 11 subtypes of leuke-
mia, except for mature B-cell leukemia, for which the 
data were sparse (Table 5). The largest racial disparities 
were noted for Burkitt lymphoma (11.7% in 1995-1999, 
14.9% in 2000-2004, and 16.1% in 2005-2009) and 
TABLE 2. Distribution (%) of leukemias in the United States, by sex and by race: 1995-2009
Sex Race
HAEMACARE 
Group
Male Female White Black Other
No. No. % No. % No. % No. % No. %
Acute lymphocytic leukemia 51,958 30,519 58.7 21,439 41.3 44,974 86.6 4,556 8.8 2,428 4.7
11 Burkitt 9,665 6,764 70.0 2,901 30.0 8,171 84.5 1,041 10.8 453 4.7
15 Lymphoblastic 
lymphoma/
acute (precursor 
cell) lympho-
blastic leukemia
25,421 14,956 58.8 10,465 41.2 21,859 86.0 2,187 8.6 1,375 5.4
20 Leukemia, NOS 16,872 8,799 52.2 8,073 47.8 14,944 88.6 1,328 7.9 600 3.6
Acute myeloid leukemia 128,626 69,488 54.0 59,138 46.0 113,280 88.1 10,136 7.9 5,210 4.1
21 Myeloid 
leukemia, NOS
4,457 2,439 54.7 2,018 45.3 3,921 88.0 392 8.8 144 3.2
22 Acute myeloid 
leukemia
124,169 67,049 54.0 57,120 46.0 109,359 88.1 9,744 7.8 5,066 4.1
Chronic lymphocytic leukemia 190,410 113,296 59.5 77,114 40.5 172,272 90.5 12,436 6.5 5,702 3.0
6 Chronic 
lymphocytic 
leukemia/small 
lymphocytic 
lymphoma
176,918 103,587 58.6 73,331 41.4 159,873 90.4 11,831 6.7 5,214 2.9
17 Mature B-cell 
leukemia
474 301 63.5 173 36.5 431 90.9 29 6.1 14 3.0
18 Mature B-cell 
leukemia, hairy 
cell
9,556 7,375 77.2 2,181 22.8 8,887 93.0 305 3.2 364 3.8
19 Lymphatic 
leukemia
3,462 2,033 58.7 1,429 41.3 3,081 89.0 271 7.8 110 3.2
Total 370,994 213,303 57.5 157,691 42.5 330,526 89.1 27,128 7.3 13,340 3.6
Abbreviations: NOS, not otherwise specified.
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CLL/small lymphocytic leukemia (10.7% in 1995-1999, 
12.8% in 2000-2004, and 12.3% in 2005-2009). For 
patients of “other” races, survival generally was higher 
than that for white patients; however, the estimates had 
wider 95% CIs. The range in survival estimates by regis-
try also showed wide geographic disparity: from 40.9% 
in Mississippi to 56.5% in Seattle, Washington (Table 5). 
For patients with CLL, AML, and ALL, the racial differ-
ence in 5-year net survival was either constant or increas-
ing (Fig. 2).
DISCUSSION
The current study reports data from 370,994 patients 
from 43 registries covering approximately 81.0% of the 
US population over a 15-year time period. Five-year net 
survival improved from 45.0% during 1995-1999 (95% 
CI, 44.6%-45.4%) to 49.0% during 2000-2004 (95% 
CI, 48.7%-49.4%) and 52.0% during 2005-2009 (95% 
CI, 51.6%-52.3%).
For patients diagnosed between 2005 and 2009, 
survival estimates were 44.0% for ALL, 18.2% for 
AML, and 77.3% for CLL. All 3 subtypes of leukemia 
showed improvements in survival, with gains in 5-year 
net survival of 9.2% for ALL, of 6.4% for CLL, and 
of 5.5% for AML from 1995-2009. The survival gains 
in ALL may be related to the use of the more intensive 
pediatric protocols in young adults,14 and the use of 
tyrosine kinase inhibitors for patients with BCR-ABL–
positive ALL.15 Fludarabine-containing regimens were 
introduced as first-line treatment for patients with 
CLL in the 1990s, when these regimens were shown 
Figure 2. The absolute age-standardized 5-year net survival difference (shown as percentage) in principal groups between black 
(B), white (W), and other (O) races for leukemias in the United States, 1995-2009. The boxes represent the absolute difference 
between B and W races. Point estimates for B, W, and O races are shown on the x-axis. The 95% confidence intervals for W 
and B patients are shown by error bars. ALL indicates acute lymphocytic leukemia; AML, acute myeloid leukemia; CLL, chronic 
lymphocytic leukemia. [Colour figure can be viewed at wileyonlinelibrary.com]
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to have higher event-free survival than chlorambucil.16 
The introduction of rituximab likely also has improved 
survival.17 Other than acute promyelocytic leukemia, 
anthracycline-based and cytarabine-based chemotherapy 
has been the mainstay of treatment for AML for many 
years. The more gradual survival gains observed in 
patients with AML are likely due to improvements 
in supportive care and stem cell transplantation.18 In 
addition to treatment, better residual disease monitoring 
and refining of diagnostic techniques such as flow 
cytometry, polymerase chain reaction, and fluorescence 
in situ hybridization, resulting in better prognostic 
precision and more effective management strategies, have 
contributed to survival gains in patients with leukemia.19
For patients with AML, the modest survival gains 
over 15 years can be partially explained by minimal 
improvements (1.4%) among the elderly patients (75-
99 years), for whom the disease burden is higher when 
compared with patients with ALL. Elderly patients often 
are less tolerant of cytotoxic treatment modalities due to 
frailty and comorbidities.20 Moreover, the disease itself 
has a different cytogenetic and molecular profile in elderly 
patients, which may be explained by prior chemotherapy 
or radiotherapy for previous malignancies or hematologi-
cal disorders such as myelodysplastic syndrome.21
Survival was consistently found to be higher for 
white than for black patients for nearly all subtypes of 
leukemia in all registries and throughout the 15 years be-
tween 1995 and 2009. For patients with ALL and AML, 
the racial difference in 5-year net survival is increasing. 
The gap in 5-year survival from acute leukemia between 
non-Hispanic white and African American or Hispanic 
patients was shown to increase between 1992 and 1996 
and between 2002 and 2006.22 This racial disparity is 
well established, and socioeconomic, cultural, and bio-
logical differences all have been put forward as contrib-
utors.23 In the case of AML, it was noted that nonwhite 
ethnic groups were less likely to undergo matched un-
related hematopoietic stem cell transplantation due to 
lower donor availability.24 Among patients with leukemia 
who were randomized to clinical trials, it was shown that 
racial disparities in survival disappear after controlling 
for prognostic factors and socioeconomic status.25 In the 
clinical trial setting among patients with ovarian cancer, 
Abdel-Rahman et al showed that there was no socio-
economic inequality in survival outcomes (ie, when ac-
cess to treatment is equal, these disparities disappear).26 
Reducing inequities in cancer care may go some way to-
ward reducing this disparity.
Using data from population-based cancer registries 
minimizes the selection bias associated with variably 
defined catchment areas in hospital-based registries. Of 
the 393,805 patient records submitted from registries to 
the CONCORD study, only 2.6% were ineligible due to 
incomplete data, coding errors, or being outside the age 
range, or of benign behavior. Of the remaining records, 
3.3% were registered solely from a death certificate or 
at autopsy, and were excluded because the date of diag-
nosis was unknown. The proportion of patients lost to 
follow-up was very low (0.8%). Net survival estimates for 
“other races” may be subjected to bias; these estimates 
are based on the background mortality of all races in the 
population because robust, state-specific life tables for 
individual racial groups were not available. As an exam-
ple, Asian/Pacific Islander women in low unemployment 
areas have a life expectancy of up to 90 years27 when 
compared with the population average of 80.7 years in 
the same areas. Net survival figures among this group of 
patients would be conservative due to the overestimation 
of background mortality by using life tables for all races 
combined. It is interesting to note that 5-year cause-spe-
cific survival for adults diagnosed with leukemia was 
10.1% lower in Asian/Pacific Islanders than whites in 
18 areas covered by the Surveillance Epidemiology and 
End Results program during 2008-2014, whereas the 
difference between the median age-standardized 5-year 
net survival estimates for leukemia in Asian and west-
ern populations in the CONCORD-3 study28 became 
smaller during the period 2000-2014. This suggests that 
a large part of the difference in leukemia survival between 
whites and Asian/Pacific Islanders in the SEER program 
is likely to be attributable to better access to treatment, 
rather than race.
Innovations in leukemia treatment over the last 50 
years are reflected in the survival gains presented in the 
current study, and are promoted through health policy and 
cancer control programs. The National Comprehensive 
Cancer Control Program (NCCCP), administered by the 
Centers for Disease Control and Prevention since 1998, 
funds all states, the District of Columbia, several tribes 
and tribal organizations, Puerto Rico, and several Pacific 
Island jurisdictions. Treatment and survival-specific ini-
tiatives described in NCCCP cancer plans include the 
strategic dissemination of information and educational re-
sources among providers, the general public, and patients 
with hematologic cancer and their families and increased 
awareness regarding the nature of the disease, dispari-
ties that exist among minority and underserved popula-
tions, treatment options, availability of clinical trials, and 
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support services for survivors. The continuance of these 
efforts is in part dependent on sustainable partnerships 
that can facilitate more effective community-clinical link-
ages and changes to ensure access to quality patient care 
among all patients. Future NCCCP efforts in these areas 
that specifically target black men and women with leuke-
mia may help to alleviate the racial differences in survival.
Further highlighted in the current study is the issue 
of classification when making population-based survival 
comparisons in patients with leukemia. Rare leukemias 
within a group undoubtedly have an impact on survival, 
especially if they are more prevalent in certain populations. 
HAEMACARE6 and INTERLymph29 are 2 projects that 
address this issue. The real challenge to producing sub-
type-specific estimates in population-based studies is that 
the data usually are sparse and estimates are imprecise.
CONCLUSIONS
Survival from leukemia in the United States has improved 
between 1995 and 2009, increasing in each successive 
5-year period. The results of the current study have iden-
tified major differences between disease subtype, sex, 
TABLE 5. Age-standardized 5-year net survival estimates by registry, stratified by race: 1995-2009
Registry
All Races White Black Other
NS 95% CI NS 95% CI NS 95% CI NS 95% CI
Alabama 45.9 44.2 47.6 47.0 45.2 48.9 37.1 33.3 41.3 91.7 78.7 100.0
Alaska 50.8 46.0 56.0 54.2 49.2 59.7 - - - 21.9 13.5 35.6
California 45.3 44.7 45.9 45.9 45.3 46.5 38.7 36.2 41.4 44.5 42.5 46.7
    Greater Bay Areaa 48.4 47.1 49.8 50.4 48.9 51.9 41.8 36.7 47.7 38.9 35.4 42.7
    Greater Californiaa 44.1 43.3 44.9 44.2 43.4 45.0 38.9 34.4 43.9 47.2 43.7 51.1
   Los Angelesa 45.5 44.4 46.7 46.4 45.2 47.7 36.9 33.4 40.7 46.6 43.0 50.4
Colorado 50.8 49.3 52.5 50.1 48.5 51.8 38.2 29.0 50.5 83.6 75.3 92.8
Connecticut 50.9 49.3 52.5 51.4 49.7 53.0 40.6 33.8 48.7 72.2 59.8 87.1
Delaware 44.5 41.2 48.2 45.2 41.7 49.1 36.5 28.5 46.8 66.8b 42.5b 91.1b
Florida 50.5 49.8 51.2 51.2 50.5 51.9 40.6 38.0 43.5 55.1 49.2 61.7
Georgia 47.9 46.4 49.5 49.2 47.5 50.9 43.4 40.0 47.1 45.7 35.3 59.0
   Atlantaa 48.0 45.7 50.4 50.5 47.9 53.2 41.1 36.5 46.3 27.9 19.6 39.7
Hawaii 43.8 40.8 47.0 57.6 52.5 63.1 - - - 34.9 31.5 38.8
Idaho 50.8 48.2 53.6 51.2 48.6 53.9 - - - 29.2b 10.1b 48.2b
Iowa 52.9 51.3 54.5 52.8 51.3 54.4 35.0b 17.9b 52.1b 86.3b 72.9b 99.7b 
Kentucky 49.3 47.8 50.8 49.5 47.9 51.1 41.4 34.9 49.1 79.3b 67.1b 91.7b
Louisiana 45.1 43.6 46.6 47.1 45.4 48.8 37.3 34.0 40.9 56.7b 40.3b 73.2b 
Maryland 41.3 39.7 43.0 42.0 40.3 43.9 36.2 32.4 40.5 63.2 53.8 74.3
Massachusetts 49.9 48.7 51.2 49.6 48.3 50.9 45.4 38.7 53.3 76.8 68.4 86.3
Michigan 47.6 46.7 48.5 47.7 46.8 48.7 39.3 36.3 42.5 75.5 68.3 83.4
   Detroita 47.8 46.4 49.3 49.1 47.5 50.8 40.0 36.6 43.8 69.0 58.1 82.0
Mississippi 40.9 37.5 44.6 41.8 38.1 45.9 38.7 31.8 47.1 31.3 34.8 59.2
Montana 49.8 46.7 53.1 49.5 46.4 52.9 - - - 58.2 45.7 74.0
Nebraska 51.3 49.2 53.6 50.9 48.8 53.2 36.4b 21.1b 51.7b 81.8b 70.6b 93.0b
New Hampshire 55.4 52.7 58.2 55.2 52.6 58.1 - - - 60.7b 39.5b 81.9b
New Jersey 49.9 48.9 50.9 50.8 49.7 51.8 36.6 33.1 40.4 64.2 57.0 72.2
New Mexico 52.5 50.1 55.0 53.3 50.9 55.8 40.7b 24.2b 57.3b 27.5 19.2 39.5
New York 48.8 48.1 49.5 49.9 49.1 50.6 38.6 36.3 41.0 52.3 47.7 57.5
North Carolina 48.5 47.3 49.7 49.4 48.1 50.7 43.4 40.0 47.0 53.1 44.2 63.8
Ohio 47.0 45.7 48.2 47.2 45.9 48.5 41.0 36.7 45.9 61.6 53.0 71.5
Oklahoma 42.3 40.6 44.1 42.6 40.8 44.5 28.1 21.6 36.4 47.5 40.3 56.0
Oregon 48.8 47.1 50.6 48.3 46.6 50.1 43.8 31.3 61.2 63.6 54.6 74.1
Pennsylvania 48.1 47.3 48.9 48.2 47.4 49.1 40.2 36.8 43.8 66.9 61.3 73.0
Rhode Island 48.4 45.4 51.5 48.9 45.9 52.1 17.4 9.0 33.4 54.3b 28.8b 79.9b
South Carolina 46.9 45.3 48.6 48.7 46.8 50.6 37.9 34.3 41.8 70.3 57.7 85.7
Tennessee 47.5 45.2 49.8 48.3 45.9 50.7 35.5 29.6 42.6 52.9 37.3 75.0
Texas 50.4 49.6 51.1 50.5 49.8 51.3 44.0 41.3 46.8 70.8 65.5 76.5
Utah 50.9 48.5 53.4 51.0 48.6 53.6 41.4b 11.3b 71.6b 45.8b 31.0b 60.5b
Washington 55.4 54.2 56.7 55.6 54.3 56.9 49.9 39.5 63.0 54.8 48.9 61.4
   Seattlea 56.5 55.0 58.1 57.4 55.8 58.9 51.6 40.3 66.2 42.2 35.9 49.5
West Virginia 46.0 43.9 48.3 45.8 43.7 48.1 49.6b 35.5b 63.7b 71.2b 33.7b 100.0b
Wisconsin 53.2 51.9 54.4 53.3 52.1 54.6 49.1 41.3 58.4 49.2 40.6 59.6
Wyoming 53.5 49.1 58.3 53.2 48.7 58.0 - - - - - -
Total 47.5 47.3 47.7 47.8 47.5 48.0 40.8 40.1 41.6 54.7 53.6 55.8
Abbreviations: 95% CI, 95% confidence interval; NS, net survival.
aMetropolitan registries.
bUnstandardized estimates.
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and race, with the relative gains in survival mirroring the 
treatment milestones that have been achieved for each 
subtype. Although the survival gap between sexes appears 
to be converging, the racial gap has not. This could have 
many causes, but addressing the sociopolitical, economic, 
and cultural constraints that create barriers to treatment, 
trial enrolment, and donor availability will be required to 
reduce inequities in access to quality cancer care.
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